Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum TELESTA THERAPEUTICS INC T.TST

"Telesta Therapeutics Inc is a biopharmaceutical company. The Company is engaged in the research, development, manufacturing and commercialization of human health products and technologies."

TSX:TST - Post Discussion

TELESTA THERAPEUTICS INC > Partnership negociations
View:
Post by Tson99 on Mar 17, 2015 11:55am

Partnership negociations

What happens to partnership negociations after the BLA has been summitted? I think that if the BLA is successfully submitted the price for partnership automatically goes up. The longer a potential partner waits the more they are going to have to pay.

They extended their self-imposed deadline for BLA summission until the end of June....what if they end up submitting early??

Cheers longs,
Tson99
Comment by DamnYankees on Mar 17, 2015 12:18pm
Right now the smart money is betting on a financing and go it alone strategy, which will not be well received when formalized. The "welcome back to the teens" sign will be flashing in neon for that occasion. With a partnership the point spread will definitely change and SP should gap upwards but more likely a short pop followed by a slow decline back to this level. With all the ...more  
Comment by blartar on Mar 17, 2015 1:19pm
found in to-days globe & mail; hope they are right.                   AVERAGE RATING   Of the two analysts surveyed by Reuters Estimates that cover Telesta Therapeutics Inc, the consensus rating is a strong buy. The rating changed on March 04, 2015 when it was upgraded from a buy. 
Comment by beechguy on Mar 17, 2015 2:49pm
Yankee I'm with you. That is the only explanation for our morbid share price. Berendt made it as clear as he could that they would not go it alone, but insinuated they needed optics to appear they were willing to. I can't imagine they would be that stupid and create a binary event like that. Give me some pocket change up front and a sweet back end deal upon FDA approval and let us live to ...more  
Comment by beechguy on Mar 17, 2015 2:50pm
Yankee I'm with you. That is the only explanation for our morbid share price. Berendt made it as clear as he could that they would not go it alone, but insinuated they needed optics to appear they were willing to. I can't imagine they would be that stupid and create a binary event like that. Give me some pocket change up front and a sweet back end deal upon FDA approval and let us live to ...more  
Comment by Frogger2 on Mar 17, 2015 3:39pm
Tson, I pasted a slide describing the process TST is following below. I think Your comments are valid but I think that the plan is not to take on a partner until the BLA is submitted, if TST chooses that path. I'm sure there is a long due diligence process for TST and interested parties and believe they will take their time and make the right choice by viewing as many as possible. They are ...more  
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities